ATX-01

ARTHEx Biotech Names Chris Freitag CMO as ATX-01 DM1 Program Advances

Valencia – November 04, 2026 -- ARTHEx Biotech, a clinical-stage RNA therapeutics developer, has appointed Christian (Chris) Freitag, M.D., as Chief Medical Officer, adding more than 20 years of clinical development experience to a pipeline led by ATX-01 for myotonic dystrophy type 1 (DM1).

Freitag arrives from CMO roles at Azafaros and Dynacure

Freitag most recently served as Chief Medical Officer at Azafaros, which develops treatments for rare genetic disorders. Before that, he was CMO at Dynacure, where he was responsible for medical and regulatory strategy, including clinical development of the company's lead investigational therapy for centronuclear myopathies.

Arthex Biotech Names Ex-IVERIC bio CEO Glenn Sblendorio Chairman

Valencia – – September 29, 2026 -- Arthex Biotech has appointed Glenn Sblendorio, former CEO of IVERIC bio, as Chairman of its Board of Directors as the clinical-stage RNA therapeutics company advances its lead program ATX-01 through Phase I/IIa trials for myotonic dystrophy type 1 (DM1).

Sblendorio brings three decades of biotech exit experience to Arthex's board

Sblendorio most recently led IVERIC bio, Inc. as CEO until its acquisition by Astellas Pharma, Inc. He previously served as President and Chief Financial Officer of The Medicines Company through its acquisition by Novartis, and as Executive Vice President and CFO of Eyetech Pharmaceuticals, Inc. until it was acquired by OSI Pharmaceuticals, Inc. Earlier in his career he was a Managing Director at MPM Capital Advisors.